SP38

SP38 is a novel, target-selective small molecule modulator of Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) signaling. Unlike traditional ATP-competitive ERK inhibitors, SP38 is designed to bind the FRS (substrate-binding domain) of ERK2. This selective binding inhibits the interaction between ERK2 and specific downstream transcription factors, notably Activator Protein-1 (AP-1), thereby suppressing the expression of AP-1 components such as FRA-1 and FosB. Developed through computational approaches by researchers at the University of Maryland and Thomas Jefferson University, SP38 has demonstrated the ability to attenuate airway smooth muscle (ASM) cell proliferation and reduce α-SMA expression in 3D spheroid models without significant cytotoxicity. Its primary therapeutic potential lies in treating airway remodeling associated with chronic asthma and other respiratory conditions characterized by ASM hyperplasia.